S174 Reduction of exacerbations according to type 2 inflammatory biomarkers with dupilumab treatment in patients with chronic obstructive pulmonary disease

作者
Simon Couillard,Sanjay Ramakrishnan,Ian Douglas Pavord,Yunus Çolak,Roland Buhl,Gaëtan Deslée,Déborah Bauer,M Soliman
出处
期刊:Thorax [BMJ]
卷期号:: A122.2-A122
标识
DOI:10.1136/thorax-2025-btsabstracts.180
摘要

Purpose In BOREAS and NOTUS, add-on dupilumab reduced moderate-or-severe exacerbation rates and improved lung function in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. This post hoc analysis explored the predictive value of baseline blood eosinophil counts and fractional exhaled nitric oxide (FeNO) for response to dupilumab treatment in patients with COPD and type 2 inflammation. Methods BOREAS (NCT03930732) and NOTUS (NCT04456673), Phase 3, randomized, placebo-controlled trials, enrolled 1874 patients (aged 40–85) COPD with moderate-to-severe airflow obstruction, and type 2 inflammation (screening blood eosinophil count ≥300 cells/mL) on triple inhalation therapy. Patients received dupilumab 300 mg every two weeks (q2w) or placebo for 52 weeks. Treatment rate ratios of dupilumab vs placebo and adjusted annualized moderate-or-severe exacerbation rates over a range of type 2 biomarkers were evaluated. Results The treatment rate ratio for moderate-or-severe exacerbations was 0.70 (95% confidence interval [CI]:0.61–0.81), 0.71 (0.61–0.83), 0.71 (0.61–0.83), and 0.72 (0.61–0.83) for patients with baseline blood eosinophil counts of 300, 500, 700, or 900 cells/µL, respectively (continuous biomarker-by-treatment interaction P=0.09). Reductions in exacerbation rates were observed over a range of baseline blood eosinophil counts (dupilumab: 0.57 [95% CI:0.51–0.63] for 300 cells/mL to 0.58 [0.51–0.65] for 900 cells/mL]; placebo: 0.81 [0.73–0.89] for 300 cells/mL to 0.81 [0.73–0.89] for 900 cells/mL). Furthermore, the treatment rate ratio for moderate-or-severe exacerbations was 0.69 (95% CI:0.59–0.80) and 0.67 (0.53–0.85) for patients with baseline immunoglobulin E (IgE) levels 100 IU/mL and 1000 IU/mL, respectively (continuous biomarker-by-treatment interaction P=0.83); reductions in exacerbation rates were observed regardless of baseline IgE levels (dupilumab: 0.56 [95% CI:0.50–0.63] for 100 IU/mL to 0.53 [0.44–0.63] for 1000 IU/mL; placebo: 0.82 [0.74–0.90] for 100 IU/mL to 0.78 [0.67–0.92] for 1000 IU/mL). Reductions in treatment rate ratio for exacerbations were also observed with increasing baseline FeNO levels from 0.69 (95% CI:0.60–0.80) for 20 parts per billion (ppb) to 0.56 (0.46–0.69) for 40 ppb (continuous biomarker-by-treatment interaction P=0.006), indicating a significant predictive value. Conclusion Dupilumab vs placebo reduced exacerbations independently of baseline blood eosinophil counts and IgE. Higher baseline FeNO levels were associated with a greater exacerbation reduction with dupilumab treatment compared with placebo.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小兔叽完成签到 ,获得积分10
1秒前
认真觅荷完成签到 ,获得积分10
2秒前
吕洺旭完成签到,获得积分10
2秒前
Maho完成签到,获得积分10
2秒前
学习通完成签到,获得积分10
3秒前
宸昶完成签到,获得积分10
3秒前
3秒前
4秒前
忧伤小芒果完成签到,获得积分10
4秒前
Jonah完成签到 ,获得积分10
4秒前
贪玩亦云完成签到,获得积分10
4秒前
yy66_发布了新的文献求助10
5秒前
6秒前
沃森完成签到 ,获得积分10
6秒前
7秒前
余香的应助被典雅的雪晴采纳,获得10
7秒前
丘比特的应助被嘎嘣脆采纳,获得10
7秒前
过海八仙完成签到 ,获得积分10
8秒前
炙热的香完成签到,获得积分10
9秒前
KK完成签到,获得积分10
9秒前
小鲨鱼发布了新的文献求助10
9秒前
帕尼灬尼完成签到 ,获得积分10
9秒前
踏实采波完成签到,获得积分10
10秒前
暴躁咩完成签到,获得积分10
10秒前
欢呼香芋完成签到,获得积分10
10秒前
6666发布了新的文献求助200
11秒前
纯真的志泽完成签到 ,获得积分10
11秒前
11秒前
小虫虫完成签到,获得积分10
11秒前
勤恳的新之完成签到,获得积分10
11秒前
黎谱发布了新的文献求助10
11秒前
简易完成签到,获得积分10
11秒前
yqcj59完成签到,获得积分10
11秒前
nininana完成签到,获得积分10
12秒前
12秒前
MODRIC完成签到 ,获得积分10
12秒前
珊珊发布了新的文献求助10
12秒前
故里完成签到,获得积分10
13秒前
果儿完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159212
求助须知:如何正确求助?哪些是违规求助? 9554678
关于积分的说明 21720538
捐赠科研通 7748887
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552092
邀请新用户注册赠送积分活动 2471464